Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance

Molecular and Cellular Proteomics

Volumn 11, Issue 8, 2012, Pages 453-466

  Alcolea, Maria P ^a,b   Casado, Pedro ^a   Rodríguez Prados, Juan Carlos ^a   Vanhaesebroeckp, Bart ^a   Cutillas, Pedro R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; JANUS KINASE 1; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DATA MINING; DRUG SENSITIVITY; ENZYME ACTIVITY; LEUKEMIA CELL LINE; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ACUTE DISEASE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE, NEOPLASM; HUMANS; JANUS KINASES; LEUKEMIA, MYELOID; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NIH 3T3 CELLS; PHOSPHOPEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84864803277     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M112.017483     Document Type: Article

References (60)

1. Manning, B. D. (2009) Challenges and opportunities in defining the essential cancer kinome. Sci. Signal. 2, pe15
2. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: The next generation. Cell 144, 646-674
3. Baselga, J. (2006) Targeting tyrosine kinases in cancer: The second wave. Science 312, 1175-1178
4. Baselga, J., and Albanell, J. (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12, (Suppl. 1) S35-S41
5. Benekli, M., Baumann, H., and Wetzler, M. (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 27, 4422-4432
6. Di Cosimo, S., and Baselga, J. (2008) Targeted therapies in breast cancer: Where are we now? Eur. J. Cancer 44, 2781-2790
7. Druker, B. J. (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8, S14-S18
8. Liu, P., Cheng, H., Roberts, T. M., and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644
9. Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., Bjerke, L. M., Kelland, L., Valenti, M., Patterson, L., Gowan, S., de Haven Brandon, A., Hayakawa, M., Kaizawa, H., Koizumi, T., Ohishi, T., Patel, S., Saghir, N., Parker, P., Waterfield, M., and Workman, P. (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840-5850
10. Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., Gulyas, S., Mitchell, D. Y., Herrera, R., Sebolt-Leopold, J. S., and Meyer, M. B. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462
11. Scholl, C., Gilliland, D. G., and Fröhling, S. (2008) Deregulation of signaling pathways in acute myeloid leukemia. Semin. Oncol. 35, 336-345
12. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C., Parra, J. L., Arribas, J., and Baselga, J. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022-8030
13. Schlabach, M. R., Luo, J., Solimini, N. L., Hu, G., Xu, Q., Li, M. Z., Zhao, Z., Smogorzewska, A., Sowa, M. E., Ang, X. L., Westbrook, T. F., Liang, A. C., Chang, K., Hackett, J. A., Harper, J. W., Hannon, G. J., and Elledge, S. J. (2008) Cancer proliferation gene discovery through functional genomics. Science 319, 620-624
14. Grueneberg, D. A., Degot, S., Pearlberg, J., Li, W., Davies, J. E., Baldwin, A., Endege, W., Doench, J., Sawyer, J., Hu, Y., Boyce, F., Xian, J., Munger, K., and Harlow, E. (2008) Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl. Acad. Sci. U.S.A. 105, 16472-16477
15. Grueneberg, D. A., Li, W., Davies, J. E., Sawyer, J., Pearlberg, J., and Harlow, E. (2008) Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 105, 16490-16495
16. Sawyers, C. L. (2008) The cancer biomarker problem. Nature 452, 548-552
17. Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P. A., Kaminker, J. S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J. K., Sukumar, S., Polyak, K., Park, B. H., Pethiyagoda, C. L., Pant, P. V., Ballinger, D. G., Sparks, A. B., Hartigan, J., Smith, D. R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S. D., Parmigiani, G., Kinzler, K. W., Velculescu, V. E., and Vogelstein, B. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113
18. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S. M., Fu, B., Lin, M. T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., Hidalgo, M., Leach, S. D., Klein, A. P., Jaffee, E. M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J. R., Kern, S. E., Hruban, R. H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V. E., and Kinzler, K. W. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806
19. Forbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C. Y., Jia, M., Ewing, R., Menzies, A., Teague, J. W., Stratton, M. R., and Futreal, P. A. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657
20. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. N., Goldstraw, P., Nicholson, A. G., Brasseur, F., Looijenga, L., Weber, B. L., Chiew, Y. E., DeFazio, A., Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G., Tan, M. H., Khoo, S. K., Teh, B. T., Yuen, S. T., Leung, S. Y., Wooster, R., Futreal, P. A., and Stratton, M. R. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158
21. Haber, D. A., and Settleman, J. (2007) Cancer: Drivers and passengers. Nature 446, 145-146
22. Weinstein, I. B. (2002) Cancer. Addiction to oncogenes: The Achilles heal of cancer. Science 297, 63-64
23. Cutillas, P. R., Khwaja, A., Graupera, M., Pearce, W., Gharbi, S., Waterfield, M., and Vanhaesebroeck, B. (2006) Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 103, 8959-8964
24. Cutilllas, P. R. (2006) Activitomics: Mulitiplex analysis of kinase activities by mass spectrometry, in Proceedings of the 54th American Society for Mass Spectrometry Conference of Mass Spectrometry and Allied Topics, Seattle, WA, May 28-June 1, 2006
25. Kubota, K., Anjum, R., Yu, Y., Kunz, R. C., Andersen, J. N., Kraus, M., Keilhack, H., Nagashima, K., Krauss, S., Paweletz, C., Hendrickson, R. C., Feldman, A. S., Wu, C. L., Rush, J., Villén, J., and Gygi, S. P. (2009) Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nat. Biotechnol. 27, 933-940
26. Thingholm, T. E., Jensen, O. N., and Larsen, M. R. (2009) Analytical strategies for phosphoproteomics. Proteomics 9, 1451-1468
27. Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., and White, F. M. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 104, 12867-12872
28. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., and Mann, M. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648
29. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., and White, F. M. (2007) Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc. Natl. Acad. Sci. U.S.A. 104, 5860-5865
30. Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., and Gygi, S. P. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. U.S.A. 102, 667-672
31. Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M. S., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., Walton, Z. E., Gu, T. L., Silva, J. C., Crosby, K., Shapiro, G. I., Maira, S. M., Ji, H., Castrillon, D. H., Kim, C. F., García-Echeverría, C., Bardeesy, N., Sharpless, N. E., Hayes, N. D., Kim, W. Y., Engelman, J. A., and Wong, K. K. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17, 547-559
32. Hoffert, J. D., Pisitkun, T., and Knepper, M. A. (2011) Phosphoproteomics of vasopressin signaling in the kidney. Expert Rev. Proteomics 8, 157-163
33. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., Hu, Y., Tan, Z., Stokes, M., Sullivan, L., Mitchell, J., Wetzel, R., Macneill, J., Ren, J. M., Yuan, J., Bakalarski, C. E., Villen, J., Kornhauser, J. M., Smith, B., Li, D., Zhou, X., Gygi, S. P., Gu, T. L., Polakiewicz, R. D., Rush, J., and Comb, M. J. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203
34. Sawyers, C. L. (2009) Shifting paradigms: The seeds of oncogene addiction. Nat. Med. 15, 1158-1161
35. Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J., Semaan, D. J., Chen, C., Fox, E. A., Gray, N. S., Monahan, J., Schlegel, R., Beroukhim, R., Mills, G. B., and Zhao, J. J. (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 17, 1116-1120
36. Muellner, M. K., Uras, I. Z., Gapp, B. V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., and Nijman, S. M. (2011) A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol. 7, 787-793
37. Knight, Z. A., Lin, H., and Shokat, K. M. (2010) Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137
38. Casado, P., and Cutillas, P. R. (2011) A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. Mol. Cell. Proteomics 10.1074/mcp.M110.003079
39. Savitski, M. M., Lemeer, S., Boesche, M., Lang, M., Mathieson, T., Bantscheff, M., and Kuster, B. (2011) Confident phosphorylation site localization using the Mascot Delta Score. Mol. Cell. Proteomics 10.1074/mcp.M110.003830
40. Cutillas, P. R., and Vanhaesebroeck, B. (2007) Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol. Cell. Proteomics 6, 1560-1573
41. Cutillas, P. R., Geering, B., Waterfield, M. D., and Vanhaesebroeck, B. (2005) Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: Analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol. Cell. Proteomics 4, 1038-1051
42. Nguyen, V., Cao, L., Lin, J. T., Hung, N., Ritz, A., Yu, K., Jianu, R., Ulin, S. P., Raphael, B. J., Laidlaw, D. H., Brossay, L., and Salomon, A. R. (2009) A new approach for quantitative phosphoproteomic dissection of signaling pathways applied to T cell receptor activation. Mol. Cell. Proteomics 8, 2418-2431
43. Stulemeijer, I. J., Joosten, M. H., and Jensen, O. N. (2009) Quantitative phosphoproteomics of tomato mounting a hypersensitive response reveals a swift suppression of photosynthetic activity and a differential role for hsp90 isoforms. J. Proteome Res. 8, 1168-1182
44. Bodenmiller, B., Wanka, S., Kraft, C., Urban, J., Campbell, D., Pedrioli, P. G., Gerrits, B., Picotti, P., Lam, H., Vitek, O., Brusniak, M. Y., Roschitzki, B., Zhang, C., Shokat, K. M., Schlapbach, R., Colman-Lerner, A., Nolan, G. P., Nesvizhskii, A. I., Peter, M., Loewith, R., von Mering, C., and Aebersold, R. (2010) Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci. Signal. 3, rs4
45. Fierens, C., Stöckl, D., Thienpont, L. M., and De Leenheer, A. P. (2001) Strategies for determination of insulin with tandem electrospray mass spectrometry: Implications for other analyte proteins? Rapid Commun. Mass Spectrom. 15, 1433-1441
46. Wityak, J., Hobbs, F. W., Gardner, D. S., Santella, J. B., 3rd, Petraitis, J. J., Sun, J. H., Favata, M. F., Daulerio, A. J., Horiuchi, K. Y., Copeland, R. A., Scherle, P. A., Jaffe, B. D., Trzaskos, J. M., Magolda, R. L., Trainor, G. L., and Duncia, J. V. (2004) Beyond U0126: Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg. Med. Chem. Lett. 14, 1483-1486
47. Pedranzini, L., Dechow, T., Berishaj, M., Comenzo, R., Zhou, P., Azare, J., Bornmann, W., and Bromberg, J. (2006) Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 66, 9714-9721
48. Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K., Hara, K., Tanaka, N., Avruch, J., and Yonezawa, K. (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278, 15461-15464
49. Buitenhuis, M., Coffer, P. J., and Koenderman, L. (2004) Signal transducer and activator of transcription 5 (STAT5). Int. J. Biochem. Cell Biol. 36, 2120-2124.
50. Liu, Y., Belkina, N. V., Graham, C., and Shaw, S. (2006) Independence of protein kinase C-delta activity from activation loop phosphorylation: Structural basis and altered functions in cells. J. Biol. Chem. 281, 12102-12111
51. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., et al. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771-15781
52. Martiny-Baron, G., Kazanietz, M. G., Mischak, H., Blumberg, P. M., Kochs, G., Hug, H., Marmé, D., and Schächtele, C. (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem. 268, 9194-9197
53. Duffy, M. J., O'Donovan, N., and Crown, J. (2011) Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat. Rev. 37, 151-159
54. Pajic, M., Scarlett, C. J., Chang, D. K., Sutherland, R. L., and Biankin, A. V. (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum. Genet. 130, 93-101
55. Ruvolo, P. P., Zhou, L., Watt, J. C., Ruvolo, V. R., Burks, J. K., Jiffar, T., Kornblau, S., Konopleva, M., and Andreeff, M. (2011) Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J. Cell. Biochem. 112, 1696-1707
56. Hu, M., Liu, Y., Deng, C., Han, R., Jia, Y., Liu, S., Jiang, Z., Cao, X., He, L., and Zhang, Q. (2011) Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. Leuk. Lymphoma 52, 1302-1311
57. Rumsby, M. G., Drew, L., and Warr, J. R. (1998) Protein kinases and multidrug resistance. Cytotechnology 27, 203-224
58. Luo, J., Solimini, N. L., and Elledge, S. J. (2009) Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136, 823-837
59. Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., Graham, A., Beran, G., Cassidy, A., Haggerty, C., Brown, H., Ellison, G., Dering, J., Taylor, B. S., Stark, M., Bonazzi, V., Ravishankar, S., Packer, L., Xing, F., Solit, D. B., Finn, R. S., Rosen, N., Hayward, N. K., French, T., and Smith, P. D. (2010) Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273
60. Morgan-Lappe, S., Woods, K. W., Li, Q., Anderson, M. G., Schurdak, M. E., Luo, Y., Giranda, V. L., Fesik, S. W., and Leverson, J. D. (2006) RNAi-based screening of the human kinome identifies Akt-cooperating kinases: A new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25, 1340-1348